Replies to post #53480 on Innovation Pharmaceuticals Inc (IPIX)

[ridinbulls]

Between the single dose and the issue of non-resistance there will be no room for anyone to step into the space!!

In addition, cost being considered I imagine that a single dose will be less than daptomycin so that coupled with the no resistant nature will give great formulary access from managed care organizations. But that's all down the road!

First we wait for results!

Let's name 2 scenarios and get opinions on what the approval process would be...

1. B is shown to be Non- Inferior to D.

Do we see a phase III?

2. B is shown to be superior!

Do we see phase III?

Just curious on everyones thoughts....